Company profile
Vera Therapeutics, Inc.
NASDAQ:VERABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Traxivitug | phase2 | — | 2 | completed, withdrawn |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06674577 | phase2 | enrolling_by_invitation | 2024-12-01 | 2031-05-21 | Vera Therapeutics, Inc. | A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept |
| NCT04294472 | phase2 | completed | 2020-08-05 | 2022-02-10 | Vera Therapeutics, Inc. | A Safety, Pharmacokinetics and Efficacy Study of MAU868 for the Treatment of BK Viremia in Kidney Transplant Recipients |
| NCT06983028 | phase2 | recruiting | 2025-07-07 | 2027-11-01 | Vera Therapeutics, Inc. | Atacicept in Multiple Glomerular Diseases |
| NCT05609812 | phase3 | withdrawn | 2022-11-02 | 2026-03-15 | Vera Therapeutics, Inc. | Atacicept in Subjects With Active Lupus Nephritis (COMPASS) |
| NCT04716231 | phase3 | active_not_recruiting | 2023-06-29 | 2025-05-15 | Vera Therapeutics, Inc. | Atacicept in Subjects With IgA Nephropathy |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 761486 | BLA | Vera Therapeutics, Inc. | ||||
Loading… | ||||||